We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Evaluating the Efficacy of Sequential Biologic Therapies for Rheumatoid Arthritis Patients with an Inadequate Response to Tumor Necrosis Factor-Alpha Inhibitors

Read time: Less than a minute

Methods

A systematic search was undertaken to identify published peer-reviewed articles that reported clinical outcomes of biologic treatment among RA patients with an inadequate response to TNF-alpha inhibitors. Data were systematically abstracted. Efficacy rates were estimated for groups of patients who differed in the number of prior TNF-alpha inhibitors used. Endpoints included ACR- (American College of Rheumatology), EULAR- (European League Against Rheumatism) and DAS (Disease Activity Score) 28-based response criteria.

Results

The search identified 41 publications, of which 28 reported biologic treatment outcomes for RA patients with prior exposure to TNF-alpha inhibitors. Seven publications reported outcomes obtained in randomized clinical trials, while the remaining consisted of observational studies. The likelihood of responding to a subsequent biologic treatment decreased as the number of previous treatments with TNF-alpha inhibitors increased for 6 out of the 8 response criteria examined.

Conclusions

For patients with prior exposure to TNF-alpha inhibitors, likelihood of response to subsequent treatment with biologic agents declines with increasing number of previous treatments with TNF-alpha inhibitors.

The full, provisional article is published online within the journal, Arthritis Research and Therapy and is free to access.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.